The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
AAML 1421, a phase I/II study of CPX-351 followed by fludarabine, cytarabine, and G-CSF (FLAG) for children with relapsed acute myeloid leukemia (AML): A Report from the Children’s Oncology Group.
 
Todd Michael Cooper
Employment - Juno/Celgene (I)
Stock and Other Ownership Interests - Juno/Celgene (I)
 
Michael Absalon
Research Funding - Celator (Inst)
 
Todd Allen Alonzo
No Relationships to Disclose
 
Robert B Gerbing
Stock and Other Ownership Interests - Pfizer
 
Kasey Joanne Leger
Consulting or Advisory Role - Jazz Pharmaceuticals
Research Funding - Abbott Laboratories
Travel, Accommodations, Expenses - Jazz Pharmaceuticals
 
Betsy A Hirsch
No Relationships to Disclose
 
Jessica Anne Pollard
No Relationships to Disclose
 
Bassem I. Razzouk
No Relationships to Disclose
 
Richard Aplenc
Honoraria - Sigma-Tau
Expert Testimony - Wiggin and Dana
Travel, Accommodations, Expenses - Sigma-Tau
 
E. Anders Kolb
No Relationships to Disclose